Storm shows PoC for RNA epigenetic inhibitor as field moves toward clinic

Storm Therapeutics unveiled what it called the first in vivo proof-of-concept data for a small molecule inhibitor of an RNA epigenetic enzyme. Data were presented Wednesday at the inaugural RNA Epigenetics in Human Disease Conference in Cambridge, U.K.

RNA epigenetics is a young field comprising at least two other preclinical companies -- Accent Therapeutics Inc. (Lexington, Mass.) and Gotham Therapeutics Corp. (New York, N.Y.) -- developing small molecules targeting RNA modifying enzymes to control gene expression (see “Taking RNA Epigenetics by Storm”; “Accent on RNA”; and “Gotham’s RNA Utility Belt”)...